The U.S. Food and Drug Administration has reportedly given the green light to begin clinical trials of pig heart transplantation in humans.
If you are not happy with the results below please do another search
50 search results for:
Coronavirus vaccines tweaked to include the Omicron variant strain can improve protection when used as a booster, the European Medicines Agency and other global health regulators said on Friday.
The COVAX facility, backed by the World Health Organization and the Global Alliance for Vaccines and Immunization, has delivered 1.55 billion COVID-19 vaccine doses to 146 countries. In December, COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.
Just days after the U.S. Supreme Court abolished women’s constitutional right to abortion, Alabama has cited that ruling in a bid to outlaw parents from obtaining puberty blockers and certain other medical treatment for their transgender children.
Under the expanded deal, AstraZeneca’s will have access to Oxford Biomedica’s Oxbox manufacturing facility to produce its shot on an as-needed basis beyond 2022.
Novartis prefers a spinoff of its generic drug unit over a potential sale to private equity firms, Bloomberg News reported on Thursday, citing people familiar with the matter.
The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.
The U.S. Supreme Court on Thursday declined to hear a challenge to New York’s mandate that healthcare sector workers be vaccinated against COVID-19 brought by a group of doctors, nurses and others who objected on religious grounds.
AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe, and a positive clinical trial update.
Shares of Angion Biomedica Corp. are falling fast after the company announced it had discontinued a mid-stage study of an oral tyrone kinase inhibitor in patients with primary proteinuric kidney diseases due to safety reasons. And Novo Nordisk also hit a wall, reporting that its diabetes drug Ozempic (semaglutide) failed to inprove liver fibrosis in NASH-related cirrhosis.